IMMUTEP LTD

ASX

1987

31

Australia Square,Level 32,264 George Street,Sydney,New South Wales,Australia

2000

61 2 8569 1880

Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti), an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer. Its other products include TACTI-002, a combination of efti with KEYTRUDA that is in a Phase II clinical trial for solid tumors; INSIGHT-004, a human anti-PD-L1 antibody, which is in a Phase I clinical trial to evaluate a combination of efti with avelumab; and TACTI-mel that is in a Phase I clinical trial for metastatic melanoma. The company also develops IMP761 for autoimmune disease. It has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreements with Merck KGaA, Darmstadt, Germany, and Pfizer Inc.; and partnerships with GlaxoSmithKline, Novartis, CYTLIMIC, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.